congressional psychedelics advancing therapies( path) caucus aimed accelerate support clinical research use novel substances, specifically psilocybin,- methylenedioxymethamphetamine( mdma).
better inform congressional members, bipartisan path caucus seeking input implement programs policies address range complex issues potential novel therapies may use psychedelic entactogenic drug medically supervised interpersonally supportive settings.
gain complete understanding issues associated use substances, path caucus believes taking inclusive, intentional, reasoned approach gathering input public may engender valuable insights accurately comprehensively characterize different modalities incorporate use substances also ensuring responsible, accountable, safe, ethical use.
seek information general public, received psychedelic- assisted therapies intervention, interested stakeholders, individuals entities working within bio- psycho- social- spiritual behavioral health ecosystem(, palliative care, addiction services), stresses holistic system care comprised clinical providers, counseling, peer support( courtney et al., 2023; dsouza, 2007; urutia et al., 2023).
essential receive input people organizations specialized experience implementing therapies psychedelic entactogenic drug substances administered, clinical research protocols(, depression, palliative care, substance use disorders, post- traumatic stress disorder( ptsd)), experience training others therapies.
part path caucus information gathering effort, acknowledge significant anthropological role certain psychedelic substances ayahuasca, peyote, psilocybe mushrooms.
indigenous peoples americas extensive traditions dating back hundreds thousands years, incorporated substances spiritual ceremonial ritual healing practices.
path caucus believes respectful, inclusive, cultural knowledge sharing communities may provide substantial insights, informing overall understanding, welcome input.
medications derived psychedelic entactogenic drug substances ultimately approved therapeutic indications fda, important understand risk mitigations frameworks fda established develop ways make sure supported.
aspects real- world risk reduction mitigation frameworks may include, limited, providing comprehensive transparent public education, implementing substance misuse prevention programs, minimizing potential adverse reactions, developing implementable risk mitigation, safety, ethical monitoring strategies.
moreover, vital consider best support developing adopting scalable infrastructures sustainable service delivery systems ensure proper accountability monitoring, well facilitate access equity utilization, particular focus communities may risk experiencing inequities care resulting disparate health outcomes(, veterans, uninsured, experiencing homelessness, people lower incomes, individuals living mental illness/ co- occurring substance use disorders; ortiz et al., 2022).
addition, federal agencies department veterans affairs make products available, need sure sufficient infrastructure ensure patient safety.
components, collectively addressed, may contribute responsible, accountable, safe, ethical use psychedelic entactogenic derived substances medically supervised interpersonally supportive settings.
path caucus seeks input inform potential future appropriations support collectively addressing relevant issues support necessary federal initiatives research, implementation fda regulation.
believes listening learning broader ecosystem, staying abreast potential innovative evidence-
based therapies may treat individuals behavioral health disorders refractory current treatment modalities, simultaneously undertaking proactive measures developing real- world risk reduction mitigation frameworks, help protect public health safety.
clinical data continue collected regarding safety profiles potential benefits therapies use psychedelic entactogenic drug substances across variety diagnoses major depressive disorder( mdd), treatment resistant depression( trd), demoralization, ptsd, generalized anxiety disorder( gad) substance use disorders, conjunction appropriate supervision support qualified mental health professionals( belouin et al., 2022; carhart- harris et al., 2021; davis et al., 2021; griffiths et al., 2016; jerome et al., 2020; mitchell et al., 2021; ross et al., 2016; siegel et al., 2021; xi et al., 2023).
additionally, fda granted requests breakthrough therapy designation specific development programs involving mdma treatment ptsd( multidisciplinary association psychedelic studies, 2017), psilocybin trd( compass pathways, 2018; goodwin,.
et al. 2022) mdd( khan, 2019; raison et al., 2023), cyb003 mdd( cybin, 2024), mm120( lysergide- tartrate) gad( mindmed, 2024).
breakthrough therapy designation process facilitates expedites development review certain new drugs potential address unmet medical needs.
designation available drugs intended treat serious life- threatening disease condition preliminary clinical evidence indicates drug may demonstrate substantial improvement available treatments clinically significant endpoint()( food drug administration, 2022).
noted breakthrough therapy designation mean fda made safety efficacy determination drug, breakthrough therapy designation substitute marketing approval.
currently, fda approved drug containing mdma, psilocybin, psilocybin analogs, lsd psychedelics entactogens safe effective therapeutic indication().
use substances without risk.
psychedelic(., psilocybin) entactogenic(, mdma) drug temporarily alter persons mood, thoughts, perceptions, lead heightened suggestibility, anxiety/ panic,/ paranoia, among outcomes.
psychedelics, participant experience vast changes perceptions reality, including time space.